Jean is ATV’s East Coast lead partner for healthcare investments and has been with ATV since 2002. She focuses on the life sciences and therapeutic device markets, identifying innovations viable for commercialization.
Jean represents ATV on the boards of Acceleron Pharma, Calithera Biosciences, Five Prime Therapeutics, Hydra Biosciences, Portola Pharmaceuticals, Thrasos Therapeutics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ). She also was on the boards of Hypnion, prior to its acquisition by Eli Lilly in April 2007; Proteolix, prior to its acquisition by Onyx Pharmaceuticals in November 2009; and Critical Therapeutics (NASDAQ:CRTX). She has been featured on the Forbes Midas List and was formerly a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center.
Jean has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of global sales and marketing. She also was Vice President and founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates.
Jean joined BancBoston Ventures in 1998 to lead its life sciences investments. There she led investments in Neurometrix (NASDAQ: NURU), Ironwood Pharmaceuticals (formerly Microbia) (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch. She earned an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.
Five Prime Therapeutics
Hypnion (acquired by Eli Lilly)
Proteolix (acquired by Onyx Pharmaceuticals)
Verastem (Nasdaq: VSTM)
Zeltiq Aesthetics (Nasdaq: ZLTQ)